Results 281 to 290 of about 269,130 (350)

ULCERATIVE COLITIS

Annals of Surgery, 1928
openaire   +3 more sources

Polydopamine-encapsulated modified Pulsatilla decoction: a strategy to enhance ulcerative colitis therapy. [PDF]

Chin Med
Chen YJ, Li CQ, Liu C, Zhu YJ, Wu JJ, Wu TT, Zhu HP, Hua DB, Sun HW.   +8 more
europepmc   +1 more source

High Risk of Colorectal Cancer After High‐Grade Dysplasia in Inflammatory Bowel Disease Patients

Alimentary Pharmacology &Therapeutics, EarlyView.
The advantages of colon‐sparing treatment for high‐grade dysplasia should be weighed against the higher risk of metachronous colorectal cancer and the subsequent need for stringent endoscopic surveillance. ABSTRACT Background There are limited data on colorectal cancer (CRC) risk after high‐grade dysplasia in inflammatory bowel disease.
Monica E. W. Derks, Maarten te Groen, Lauranne A. A. P. Derikx, Iris D. Nagtegaal, Frank Hoentjen   +4 more
wiley   +1 more source

Ulcerative colitis: Timeline to a cure. [PDF]

World J Gastroenterol
Pravda J.
europepmc   +1 more source

Sclerosing cholangitis: Liver transplantation [PDF]

, 1989
Marsh, JW, Starzl, TE
core  

A Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy, Faria Ahmed, Michael Pugliese, Monica Taljaard, Parul Tandon, Priscilla Matthews, Gilaad G. Kaplan, Stephanie Coward, Charles N. Bernstein, Eric I. Benchimol, M. Ellen Kuenzig, Laura E. Targownik, Harminder Singh, on behalf of the Canadian Gastro‐Intestinal Epidemiology Consortium (CanGIEC)   +13 more
wiley   +1 more source

Mirikizumab: a landmark in IL-23-targeted therapy for ulcerative colitis. [PDF]

Ann Med Surg (Lond)
Iqbal MU, Shafquat E, Khan MO, Abu Nahla U.   +3 more
europepmc   +1 more source

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
Eating disorders are common among individuals with IBD, with prevalence estimates ranging from 3% to 14% depending on the assessment method. Findings highlight the need for validated screening tools tailored to IBD. ABSTRACT Background and Aims Disentangling whether disordered eating is a cause, consequence or manifestation of inflammatory bowel ...
Quinn Goddard, Ante Markovinović, Paul E. Ronksley, Cynthia H. Seow, Christopher Ma, Abdel‐Aziz Shaheen, Gilaad G. Kaplan   +6 more
wiley   +1 more source

Chronic Ulcerative Colitis (Thrombo-Ulcerative Colitis)

Journal of the American Medical Association, 1951
openaire   +3 more sources